stockrowViatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
Follow VTRS
Alert me
Viatris Inc. (VTRS) Revenue
Viatris Inc.'s revenue for fiscal 2025 was $14.3B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $14.7B. Over the past ten years it has ranged from $9.4B (fiscal 2015) to $17.9B (fiscal 2021); the current reading is higher than 64% of that period. Revenue has fallen for 4 consecutive fiscal years. Viatris Inc. ranks 4th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $14.3B | (2.98%) |
| FY2024 | $14.7B | (4.46%) |
| FY2023 | $15.4B | (5.14%) |
| FY2022 | $16.3B | (9.08%) |
| FY2021 | $17.9B | 49.73% |
| FY2020 | $11.9B | 3.87% |
| FY2019 | $11.5B | 0.58% |
| FY2018 | $11.4B | (3.98%) |
| FY2017 | $11.9B | 7.50% |
| FY2016 | $11.1B | 17.47% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $3.7B | (0.19%) |
| Jun 2026 | $3.8B | 6.82% |
| Mar 2026 | $3.5B | (5.04%) |
| Dec 2025 | $3.7B | (1.50%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $17.2B |
| VTRS Viatris Inc. | $14.7B |
| ZTS Zoetis Inc. compare | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| UTHR United Therapeutics Corporation compare | $3.2B |
| ALKS Alkermes plc compare | $1.8B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on VTRS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement